Loading clinical trials...
Loading clinical trials...
A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.
Conditions
Interventions
SEP-363856
Placebo
Locations
2
United States
California Clinical Trials Medical Group
Glendale, California, United States
Collaborative Neuroscience Network, LLC
Long Beach, California, United States
Start Date
August 1, 2013
Primary Completion Date
March 1, 2014
Completion Date
March 1, 2014
Last Updated
June 26, 2024
NCT06894212
NCT06003036
NCT04226898
NCT05240976
NCT07455929
NCT05304767
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions